Shares of NxStage Medical, Inc. (NASDAQ:NXTM) have been given a consensus rating of “Hold” by the ten ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and nine have given a hold recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $30.00.

A number of brokerages recently commented on NXTM. Jefferies Group LLC decreased their target price on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Thursday, August 10th. Craig Hallum cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. BidaskClub cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $32.00 target price on shares of NxStage Medical in a research report on Monday, May 8th.

Shares of NxStage Medical (NASDAQ:NXTM) traded down 0.83% on Wednesday, reaching $27.53. The company’s stock had a trading volume of 1,289,061 shares. The company’s market cap is $1.82 billion. The firm has a 50 day moving average of $26.10 and a 200 day moving average of $26.00. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80.

NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The company had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.03) EPS. Analysts predict that NxStage Medical will post ($0.04) earnings per share for the current year.

In other news, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $23.29, for a total transaction of $100,147.00. Following the sale, the senior vice president now owns 29,637 shares of the company’s stock, valued at approximately $690,245.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $23.14, for a total transaction of $80,990.00. Following the sale, the senior vice president now directly owns 17,270 shares in the company, valued at approximately $399,627.80. The disclosure for this sale can be found here. Insiders sold 53,900 shares of company stock worth $1,463,316 in the last 90 days. Corporate insiders own 4.70% of the company’s stock.

A number of large investors have recently bought and sold shares of the company. Eagle Asset Management Inc. acquired a new stake in NxStage Medical during the first quarter valued at approximately $54,558,000. Karp Capital Management Corp acquired a new stake in NxStage Medical during the first quarter valued at approximately $256,000. UBS Asset Management Americas Inc. raised its stake in NxStage Medical by 148.4% in the first quarter. UBS Asset Management Americas Inc. now owns 32,532 shares of the medical device company’s stock valued at $873,000 after buying an additional 19,434 shares during the last quarter. Bank of New York Mellon Corp raised its stake in NxStage Medical by 0.5% in the first quarter. Bank of New York Mellon Corp now owns 639,866 shares of the medical device company’s stock valued at $17,168,000 after buying an additional 2,914 shares during the last quarter. Finally, Athena Capital Advisors LLC acquired a new stake in NxStage Medical during the first quarter valued at approximately $295,000. 93.20% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “NxStage Medical, Inc. (NXTM) Receives Average Rating of “Hold” from Brokerages” was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/nxstage-medical-inc-nxtm-receives-average-rating-of-hold-from-brokerages/1532483.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.